Adma Biologics Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.90%.
Did ADMA Beat Earnings? Q3 2025 Results
ADMA Biologics delivered a mixed but broadly constructive third quarter, posting revenue of $134.22 million for Q3 2025, a 12.0% year-over-year gain that cleared the consensus estimate of $130.53 million by 2.83%, even as earnings came in marginally short. Diluted GAAP EPS of $0.15 missed the $0.15 consensus by 3.23%, with the gap explained largely by a sharply higher tax provision of $11.09 million compared to just $840,000 in the year-ago period, along with a $2.18 million debt extinguishment charge tied to a refinancing. The revenue strength was driven by record utilization of ASCENIV, the company's differentiated immunoglobulin therapy, which also supported gross margin expansion to 56.3% from 49.8%, aided by yield-enhanced production batches the FDA recently cleared for commercial release. Management raised FY 2025 revenue guidance to at least $510.00 million and lifted FY 2026 revenue guidance to at least $630.00 million, while projecting total annual revenue exceeding $1.10 billion by FY 2029, underscoring confidence in sustained commercial momentum and margin improvement through the coming years.
- Continued adoption and utilization of ASCENIV by physicians, payers, and patients
- More favorable mix of higher-margin immunoglobulin sales
- Operational efficiencies reducing manufacturing costs
- Yield-enhanced production batches received FDA lot release, expected to drive margin expansion starting Q4 2025
“ADMA is executing from a position of strength as we enter our next phase of disciplined, profitable growth. The FDA lot release of our first yield‑enhanced production batches marks a pivotal milestone expected to drive sustained gross margin expansion beginning in the fourth quarter of 2025 and through 2026 and beyond. Record ASCENIV utilization and ongoing constructive negotiations with payers for enhanced 2026 reimbursement and access underscore the durable and growing demand for our differentiated plasma‑derived biologics portfolio.”
ADMA Biologics CEO, on the earnings call
Forward Guidance & Outlook
ADMA raised FY 2025 total revenue guidance to at least $510 million (from $500+ million), while modestly adjusting FY 2025 adjusted net income to approximately $158 million due to a higher effective tax rate (from $175+ million). FY 2025 Adjusted EBITDA guidance reaffirmed at $235 million. FY 2026 total revenue guidance raised to at least $630 million (from $625+ million), adjusted EBITDA raised to more than $355 million (from $340+ million), and adjusted net income raised to more than $255 million (from $245+ million), which considers a full corporate tax rate. The company projects total annual revenue to exceed $1.1 billion by FY 2029 with outsized earnings growth, excluding potential contributions from SG-001 and capacity expansion. Gross margin expansion is expected to accelerate beginning in Q4 2025 from yield-enhanced production batches, with continued gains through 2026. ASCENIV payer coverage expansion is anticipated in 2026. Working capital is expected to normalize in coming quarters, supporting accelerating cash growth through 2026.
ADMA YoY Financials
ADMA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.